PTEN Research’s Post

To help launch and support your PTEN research 🚀🔬

Final call for applications – submission deadline in 2 weeks! PTEN Research is inviting applications to advance the understanding of disease mechanisms that drive PHTS manifestations. Funding is available for basic and translational research projects addressing key knowledge gaps in the pathobiology of PHTS. We encourage projects that utilise PHTS patient-derived induced pluripotent stem cells that will be available through a biorepository later in 2024. Funding requests of up to 220,000 GBP (or the equivalent in the host institution’s local currency) will be considered, for a project of 2 to 3-years in length. Application deadline is 28 June 2024. Full details and how to apply can be found on https://lnkd.in/eiVUwV28 About PTEN Research PTEN Research is a UK-registered charity. We fund and facilitate research that will lead to new and better treatment for PHTS, a rare condition which currently has no health authority approved therapies. We do this by funding research projects and bringing together a global network of PHTS focussed experts and other key partners. About PHTS In PHTS, germline mutation of the PTEN gene increases PI3K/AKT/mTOR signalling, a key pathway regulating cell growth. Individuals with PHTS have an increased predisposition to cancer as well as various significant co-morbidities, including developmental delay, autism spectrum disorder, polyposis, vascular anomalies and hamartomas. The prevalence of PHTS is estimated to be 1:200,000 but the condition is likely under-diagnosed. #PTENResearch #PHTS #PTEN

Calling out for Grant Funding Applications! PTEN Research is inviting applications to advance the understanding of disease mechanisms that drive PTEN Hamartoma Tumour Syndrome (PHTS) manifestations. Funding is available for basic and translational research projects addressing key knowledge gaps in the pathobiology of PHTS. We encourage projects that utilise PHTS patient-derived induced pluripotent stem cells that will be available through a biorepository later in 2024. Funding requests of up to £220,000 GBP (or the equivalent in the host institution’s local currency) will be considered, for a project of 2 to 3-years in length. Application deadline is 28 June 2024. Full details and how to apply can be found on www.ptenresearch.org About PTEN Research PTEN Research is a UK-registered charity. We fund and facilitate research that will lead to new and better treatment for PHTS, a rare condition which currently has no health authority approved therapies. We do this by funding research projects and bringing together a global network of PHTS focussed experts and other key partners. About PHTS In PHTS, germline mutation of the PTEN gene increases PI3K/AKT/mTOR signalling, a key pathway regulating cell growth. Individuals with PHTS have an increased predisposition to cancer as well as various significant co-morbidities, including developmental delay, autism spectrum disorder, polyposis, vascular anomalies and hamartomas. The prevalence of PHTS is estimated to be 1:200,000 but the condition is likely under-diagnosed. #PTENResearch #PHTS #PTEN

Calling out for applications – submission deadline approaching! PTEN Research is inviting applications to advance the understanding of disease mechanisms that drive PHTS manifestations. Funding is available for basic and translational research projects addressing key knowledge gaps in the pathobiology of PHTS. We encourage projects that utilise PHTS patient-derived induced pluripotent stem cells that will be available through a biorepository later in 2024. Funding requests of up to 220,000 GBP (or the equivalent in the host institution’s local currency) will be considered, for a project of 2 to 3-years in length. Application deadline is 28 June 2024. Full details and how to apply can be found at https://lnkd.in/eiVUwV28 About PTEN Research PTEN Research is a UK-registered charity. We fund and facilitate research that will lead to new and better treatment for PHTS, a rare condition which currently has no health authority approved therapies. We do this by funding research projects and bringing together a global network of PHTS focussed experts and other key partners. About PHTS In PHTS, germline mutation of the PTEN gene increases PI3K/AKT/mTOR signalling, a key pathway regulating cell growth. Individuals with PHTS have an increased predisposition to cancer as well as various significant co-morbidities, including developmental delay, autism spectrum disorder, polyposis, vascular anomalies and hamartomas. The prevalence of PHTS is estimated to be 1:200,000 but the condition is likely under-diagnosed. #PTENResearch #PHTS #PTEN

Announcing our newly evolved funding scheme! Partnership and Impact (P&I) awards focus on establishing partnerships between 3Rs method developers and end users to accelerate uptake into routine practice. 📆 Learn more about the scheme and register for the launch webinar: https://lnkd.in/e6GbFFBP We are delighted to be continuing our collaboration with Cancer Research UK (CRUK) and British Heart Foundation offering additional joint P&I awards for grants seeking to achieve a 3Rs impact within cancer or cardiovascular research. The remit for the scheme is broad. Proposals should be tailored to the 3Rs approach and what is needed by the research field to help build confidence in the model and drive its uptake to achieve the maximum scientific and 3Rs potential. Applications should include activities to aid transfer so the 3Rs approach can be used by other researchers, for example: ✅ Building an evidence base  ✅ Demonstrating transferability  ✅ Applying the model to a new discipline 👉 Contact the Office to check your idea is in remit: 3rsgrants@nc3rs.org.uk Applicants should be UK-based, hold a graduate degree and be able to demonstrate they will direct the proposed research. Applications from less experienced researchers should be made in collaboration with a more senior colleague.

#NC3Rs Funding opportunities to build confidence in the #3Rs

🌟 Day 228 - Grant Number 213 - Grant Alert: 🌟 🌟 Exciting Grant Opportunity Alert! 🌟 We're thrilled to announce that the WCRF Regular Grant Programme is now open for applications! Dedicated to pioneering research into the effects of diet, nutrition, and physical activity on cancer prevention and survivorship, this grant supports projects that push the boundaries of our understanding and create impactful change. 🔍 Grant Details: - Investigator Initiated Grants: Up to £500,000 for projects lasting up to 4 years. - Pilot and Feasibility Grants: Up to £60,000 for projects up to 2 years. - Geographic Eligibility: Open to researchers from all over the world, excluding the Americas. 📅 Important Dates: - Outline Submission Deadline: 30 October 2024, 17:00 GMT 🌍 This is a unique opportunity for researchers based in low- or middle-income countries, as WCRF encourages you to express your interest and get involved. Whether you're at the forefront of cancer research or looking to delve into how lifestyle factors influence cancer progression and recovery, we want to hear from you! For full details on eligibility, funding, and application process, check out our guidelines document or visit our website. Don’t miss out on the chance to contribute to crucial cancer research! 🔗 Apply today and be a part of this incredible journey to understand and combat cancer more effectively! Apply on Link https://lnkd.in/ep6zqh4i #ChanakyaAdvisors #CancerResearch #WCRFGrants #ResearchFunding #GlobalHealth #CancerPrevention #NutritionResearch #PublicHealth #AcademicResearch #InnovativeResearch #GrantOpportunity

We are thrilled to announce our latest collaboration with the University of Oxford, made possible through significant Innovate UK funding as part of the #biomedicalcatalyst.   The objective of the Biomedical Catalyst grant is to take our single cell T-cell immune profiling platform beyond oncology and deploy it to investigate disease mechanisms in Ulcerative Colitis (UC). This project grants us the opportunity to comprehensively profile the UC disease microenvironment to discover novel disease targets and understand T-cell autoreactivity. Over the next 18 months, in collaboration with world-leading teams at the University of Oxford, we will deploy single-cell and computational approaches to investigate UC patient samples with the ultimate aim of informing the development of novel targeted immunomodulatory agents. This project represents a further deepening of our relationship with the University of Oxford, a relationship which goes back to the incorporation of T-Cypher Bio.   This grant will further increase the potential of our unique platforms to deliver where it matters: in the large patient populations in which immune mediated mechanisms drive unmet clinical need across oncology, autoimmune and infectious disease. We look forward to sharing further updates of our scientific, pipeline and corporate development in the coming quarters.  

There are some diseases that just don't have animal models; #Crohn's disease (CD) is one of them. 🎗 Kudos to UC San Diego UC San Diego HUMANOID: Human Organoid Center of Research Excellence (CoRE) for building a living biobank of human preclinical models for studying CD (adult stem cell derived #organoids) that are #benchmarked for #model #accuracy through rigorous computational metrics. The team discovered that despite the thunderous heterogeneity in clinical subtypes, all patients fall into just two major #disease-driving intrinsic #epithelial #phenotypes at the molecular level. Each requires its own personalized therapeutic fix with no crossover benefits! Read more (👇) on how a project this large in scope could only be pulled off because of team effort spanning the #clinic, the #bench, and the #cloud. Most importantly, HUMANOID's models are built in close collaboration with with clinician-scientists who command domain expertise; in this instance, we are grateful to UC San Diego IBD Clinic Directors, William Sandborn and Brigid Boland for access to their insights, expertise, patients, and clinics. Link to news: https://lnkd.in/gb2JTqG2   Link to article: https://lnkd.in/gZFUuF9Z A big shout out to the team of co-authors: Courtney Tindle, Ayden Fonseca, @sahar Taheri, Gajanan Dattatray Katkar, Jasper Lee, Priti Prasanna Maity, Ibrahim M Sayed, Stella-Rita Ibeawuchi, Eleadah Vidales, Rama Pranadinata, Mackenzie Fuller, Dominik Stec, Mahitha Shree Anandachar, Kevin Perry, @helen N. Le, Jason Ear, Brigid Boland, William Sandborn, Debashis Sahoo, Soumita Das and Pradipta Ghosh. #Grateful to #funders: The Helmsley Charitable Trust, and in part by National Institute of Allergy and Infectious Diseases (NIAID), National Center for Advancing Translational Sciences (NCATS).

We’re delighted to announce our involvement in a ground-breaking research study that is set to change the way we access genetic testing in the future.   DETECT-2 is a research study aiming to evaluate offering genetic testing to patients diagnosed with bowel, womb, and ovarian cancer at home.   By comparing home-based testing with traditional hospital-based methods, the study is set to uncover insights into patient acceptance, satisfaction, and the impact on mental well-being and quality of life.   Everything Genetic's newly appointed Chief Operating Officer, David Hutchinson said: “Supporting a study like DETECT-2 means that Everything Genetic is actively involved in advancing patient care in the field of cancer genetics.    “As a key partner in the project, we are contributing logistical expertise for the distribution of test kits, facilitating the automated documentation and reporting process through our custom-built online portal, and providing a clinical-grade genetic testing service to analyse specific genes. We look forward to supporting the DETECT-2 study team and eagerly await the research findings.”   The study, which has just been launched, is being led by Queen Mary University of London (Chief Investigator: Professor Ranjit Manchanda) and delivered by a network of NHS hospital sites across the UK. Funded by GSK, the North East London Cancer Alliance, Barts Charity and the North Central London Cancer Alliance.   The study is now open for recruitment at Barts Health NHS Trust, with additional sites across the UK set to join in the coming months.   For more information about DETECT-2, visit: https://lnkd.in/ePA-D5NN   #EverythingGenetic #DETECT2 #GeneticTesting #CancerResearch #Innovation #PatientCare #WomenPrecisionPrevention #WPP